The 15-20 National Hospital in Paris and GenSight Biologics have announced a significant development for patients with Leber Hereditary Optic Neuropathy, with the first patients now treated in France under the named patient early access program for GS010, also known as LUMEVOQ. The milestone, disclosed on March 20, 2026, means French patients with vision loss linked to the ND4 mitochondrial mutation now have a real-world pathway to receive the investigational gene therapy outside the formal clinical study route, even as the parallel REVISE dose study continues to advance.
The first group of patients in the French AAC program received treatment at the 15-20 National Hospital on March 19, 2026, with additional treatments already planned in the coming weeks. That makes GS010 early access one of the most closely watched rare disease access developments in French ophthalmology this month, especially because Leber Hereditary Optic Neuropathy remains a severe and fast-moving condition with limited treatment options for many affected patients.
GS010 early access expands options for ND4 LHON patients in France
GS010 is a gene therapy candidate in clinical development for Leber Hereditary Optic Neuropathy caused by a mutation in the ND4 mitochondrial gene. This inherited disease causes sudden and often irreversible vision loss as retinal ganglion cells degenerate. GenSight Biologics and clinicians at the 15-20 National Hospital are effectively positioning LUMEVOQ treatment access as an urgent intervention pathway because these cells continue to deteriorate over time, narrowing the window in which treatment may still offer benefit.
Under France’s named patient early access framework, the ANSM authorized treatment for patients presenting with vision loss related to ND4-LHON. The company and hospital said the ND4 mutation is the most common major mutation behind LHON and is associated with the poorest visual prognosis among the three most prevalent mutations, which helps explain why the French AAC program is attracting attention from clinicians, patients and rare disease observers.
In indirect remarks attributed to Nicolas Péju, Chief Executive Officer of the 15-20 National Hospital, the hospital said it is providing LHON patients access to GS010 within a strict regulatory framework and that its clinical teams are fully mobilized to support patients through either the REVISE dose study or the AAC pathway. That framing underscores how the French AAC program is being presented not as a shortcut around regulation, but as a controlled access mechanism for a high-need patient group.
REVISE dose study continues alongside the French AAC program
The REVISE dose study remains a central part of the clinical and regulatory story. GenSight Biologics said the REVISE dose-ranging study was authorized by the ANSM and the Ethics Committee in December 2025 and began according to plan in early 2026. The first patient in that study was treated in February 2026, and three additional patients have since been enrolled. French patients eligible for both the clinical study and the AAC pathway are being prioritized for the clinical trial in line with applicable regulations.
That dual-track setup is important. The French AAC program addresses immediate treatment access needs for ND4 LHON patients, while the REVISE dose study is intended to generate structured evidence on dose selection and clinical performance. In practical terms, GenSight Biologics now has two active routes in France tied to the same asset: one for controlled patient access and another for ongoing clinical development. This increases visibility for the GS010 early access story while also keeping the LUMEVOQ regulatory pathway anchored to prospective study data.
In indirect comments, GenSight Biologics Chief Medical Officer Magali Taiel said the first AAC treatments turn access to GS010 into a concrete reality for many ND4 mutation patients who would otherwise have no suitable treatment option, and that France now offers two routes for these patients through the AAC program and the REVISE study. That assessment highlights the central medical message of the announcement: access is broadening even before a potential later-stage readout or wider commercialization decision.
What this means for GenSight Biologics and rare disease treatment access
For GenSight Biologics, the announcement carries significance beyond a simple treatment milestone. It shows the company moving from regulatory preparation into patient administration at a time when execution matters greatly for small listed biotechnology groups. On Euronext Paris, GenSight Biologics shares were last quoted at about €0.0843 on March 18, 2026, according to Euronext data. The stock has been trading at very low absolute levels, and the company recently disclosed a fundraising worth nearly €1.7 million, underscoring the financially sensitive environment in which these operational milestones are unfolding.
The sentiment around this update is cautiously positive. From a clinical and strategic standpoint, first treatments under the French AAC program represent tangible progress for a company working in a difficult rare disease segment. They suggest that regulatory engagement with French authorities has advanced enough to support actual patient use, and they reinforce that GS010 remains GenSight Biologics’ lead value driver. At the same time, investor sentiment is likely to remain measured because early access treatment does not by itself resolve larger questions around long-term efficacy, broader approvals, commercial uptake and financing needs. That is an inference based on the company’s recent capital raise, current share price level and the fact that the REVISE dose study is still ongoing.
More broadly, the development reflects a growing trend in rare disease medicine, where early access pathways are becoming increasingly important for patients facing rapidly progressive conditions. In this case, GS010 early access and the REVISE dose study are now moving in parallel, giving ND4 LHON patients in France a rare combination of structured study participation and named patient treatment access while GenSight Biologics continues to build its evidence base.